https://doi.org/10.4081/hmr.v1i5.634

Progress and prognosis in chronic lymphocytic leukaemia

Vol. 1 No. 5: Changing the paradigm: new perspectives in the treatment of haematological malignancies
Published: June 17, 2009
Abstract Views: 161
PDF: 286
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Stephan Stilgenbauer
support@pagepress.org
Chronic lymphocytic leukaemia (CLL) follows an extremely variable clinical course with survival ranging from months to decades. In recent years, although effective therapeutic approaches for CLL have been developed, some patients remain primarily refractory or develop resistance to such treatment during the course of the disease. This situation is associated with a particularly poor prognosis and short survival time. Molecular and cellular markers that may predict for refractory disease and disease progression in patients with CLL have recently been identified. Genomic aberrations, mutational profile of immunoglobulin heavy chain genes and ZAP-70 expression provide prognostic information for individual patients independently of clinical disease characteristics. These molecular markers have now entered the stage of risk stratification for individual patients in clinical trials.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Stilgenbauer, S. (2009). Progress and prognosis in chronic lymphocytic leukaemia. Hematology Meeting Reports (formerly Haematologica Reports), 1(5). https://doi.org/10.4081/hmr.v1i5.634
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).